Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Metastatic Pancreatic Adenocarcinoma 1Lung Neoplasms 1Gastrooesophageal Cancer 1Colorectal Neoplasms 1Colonic Neoplasms 1Colonic Diseases 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Gemcitabine 6Fluorouracil 5Leucovorin 4Irinotecan 3Albumin-Bound Paclitaxel 3pembrolizumab 2irinotecan sucrosofate 2Oxaliplatin 24-fluorobenzoyl-TN-14003 2zolbetuximab 1regorafenib 1olaparib 1ibrutinib 1beta-D-glucosylisophosphoramide mustard 1adavosertib 1Tetrahydrouridine 1Telemedicine 1Taxes 1Practice Guidelines as Topic 1Paclitaxel 1PEGPH20 1Erlotinib Hydrochloride 1Drug Therapy 1Docetaxel 1Decitabine 1Counseling 1Cisplatin 1Capecitabine 1BKT140 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Pancreatic Adenocarcinoma × ibrutinib × Gastrointestinal × Clear all
NCT02562898 2021-05-06

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

University of California, San Francisco

Phase 1/2 Completed
18 enrolled 15 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡